EP2611434A1 — Pharmaceutical composition comprising metformin and pioglitazone
Assigned to Lupin Ltd · Expires 2013-07-10 · 13y expired
What this patent protects
A pharmaceutical composition comprising metformin or pharmaceutically acceptable salts, esters, solvates, hydrates, metabolites, prodrugs or isomers thereof in extended release form and pioglitazone or pharmaceutically acceptable salts, esters, solvates, hydrates, metabolites, pr…
USPTO Abstract
A pharmaceutical composition comprising metformin or pharmaceutically acceptable salts, esters, solvates, hydrates, metabolites, prodrugs or isomers thereof in extended release form and pioglitazone or pharmaceutically acceptable salts, esters, solvates, hydrates, metabolites, prodrugs or isomers thereof in immediate release form is provided. More particularly a pharmaceutical composition comprising extended release metformin core comprising metformin, extended release polymer and other pharmaceutically acceptable excipients; and immediate release pioglitazone layer comprising pioglitazone, high viscosity polymer, and other pharmaceutically acceptable excipients. Further a pharmaceutical composition comprising extended release metformin core comprising metformin, extended release polymer and other pharmaceutically acceptable excipients; and immediate release pioglitazone layer comprising pioglitazone, polyvinyl alcohol, surfactant and other pharmaceutically acceptable excipients
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.